Investigation and analysis on the charging status and standard of pharmacy intravenous admixture service in China
The lack of a unified inspection and evaluation standard as well as charging standard in China is currently an urgent issue that needs to be addressed. The existing charging standard falls below the recommended level, thus it is necessary to develop a more reasonable and equitable charging standard that takes into account operational costs. This study can serve as an empirical reference for national medical insurance and health administration authorities in establishing unified regulatory standards and dynamic pricing adjustment mechanisms for PIVAS. It contributes to the transition of PIVAS from "regionally fragmented management" to "nationally standardized operations," thereby supporting the dual objectives of enhancing healthcare service quality and optimizing the utilization efficiency of medical insurance funds.
Authors
- Jie Cao (ORCID: https://orcid.org/0000-0003-0256-761X)
- Jie Li (ORCID: https://orcid.org/0000-0002-9128-0727)
- Dan Wang (ORCID: https://orcid.org/0000-0003-4804-9578)
- Xuefeng Cai (ORCID: https://orcid.org/0000-0001-7459-9237)
- Shu Zhou (ORCID: https://orcid.org/0000-0003-4208-0312)
- Yong-Ning Lyu (ORCID: https://orcid.org/0000-0003-4753-6788)
Institutions
- Union Hospital (HK)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.3389/fphar.2025.1648571
- Primary Topic
- Safe Handling of Antineoplastic Drugs
- Type
- article
- Field-Weighted Citation Impact
- 0.00